MAPT and Alzheimer disease: However, in the context of AD, chronic activation of microglia driven by amyloid-β deposition, tau pathology, and persistent inflammatory cues (e.g., IL-1β, TNF-α) leads to excessive release of MMP-2, MMP-9, and cathepsins, which enzymatically degrade PNN components [126].